List view / Grid view
6 December 2016 | By Niamh Louise Marriott, Digital Editor
The new technology makes sure the privacy of genomic information is not compromised as patients’ data go through various processing steps...
6 December 2016 | By Niamh Louise Marriott, Digital Editor
NovoSeven, a portable room temperature stable recombinant activated factor VIIa, resolved 96.5% of bleeds demonstrating efficacy with haemophilia...
6 December 2016 | By Niamh Louise Marriott, Digital Editor
Results from the Phase II study show that SEG101 an anti-P-selectin antibody, reduced the median annual rate of sickle cell-related pain crises by 45.3%...
5 December 2016 | By Niamh Louise Marriott, Digital Editor
The updated US label for Veltassa recommends patients take Veltassa at least 3 hours before or 3 hours after other oral medications...
5 December 2016 | By Niamh Louise Marriott, Digital Editor
All employees of PII will join Perigord, with the combination expected to deliver the most robust menu of labelling and labelling-related services...
5 December 2016 | By Niamh Louise Marriott, Digital Editor
In earlier draft guidance, NICE’s appraisal committee had not recommended pembrolizumab as there were uncertainties about its long term benefits...
5 December 2016 | By Niamh Louise Marriott, Digital Editor
Mepolizumab is the first biologic treatment to target specific white blood cells called eosinophils, which are responsible for symptoms of severe asthma...
5 December 2016 | By Niamh Louise Marriott, Digital Editor
Guselkumab is a human monoclonal antibody that targets the protein interleukin (IL)-23, which has been shown to play a key role in the development...
5 December 2016 | By Niamh Louise Marriott, Digital Editor
The XEN Glaucoma Treatment System reduces intraocular pressure in patients and is indicated for the management of refractory glaucomas...
2 December 2016 | By Niamh Louise Marriott, Digital Editor
Ibrutinib had only previously been available through the CDF. Following a reduction in its price for the NHS, it is now recommended in further guidance...
30 November 2016 | By
A team of scientists found that a potential new stroke drug not only works in rodents by limiting the death of existing brain cells but also by promoting...
29 November 2016 | By Wickham Laboratories Limited
Wickham Laboratories completes facility expansion for growing sterility department...
29 November 2016 | By Niamh Louise Marriott, Digital Editor
Soliqua 100/33 is the combination of Lantus (insulin glargine 100 Units/mL) and lixisenatide, a GLP-1 receptor agonist, studied in a Phase 3 program...
28 November 2016 | By Niamh Louise Marriott, Digital Editor
It is the first time that a form of acute leukaemia can be effectively treated with a regimen that is entirely chemotherapy-free...
24 November 2016 | By Edinburgh Instruments
Edinburgh Instruments are pleased to announce that we have been accepted to the Scottish Business Pledge, as part of its ongoing commitment to delivering fairness and equality in the work place...
